Insulin Pen - Search News

FDA approves 1st rapid-acting insulin

FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like i

KIRO-TV · 5h

FDA approves first rapid-acting insulin

According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes.

Hosted on MSN · 6h

Sanofi gets FDA approval for NovoLog insulin biosimilar

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus.

Business Insider · 7h

FDA approves Sanofi biosimilar product for treatment of diabetes

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric

MarketWatch · 8h

FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

Agency Continues Efforts to Increase Access to Insulin Treatment Options SILVER SPRING, Md., /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.

Healio5h

FDA approves subcutaneous Merilog for glycemic control in diabetes

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The New York Times1mon

Insulin Prices Dropped. But Some Poor Patients Are Paying More.

That was the case for Lorena Sarmiento, another patient at Erie Health who uses Lantus, an insulin pen. Last fall, after the 340B discount changed, she was quoted $490 at her pharmacy — the ...

Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR | MarketsandMarkets™

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...

Orange County Business Journal4d

Beta Bionics Debuts at Nearly $1B Value

Beta Bionics’ IPO marks one of the largest public offerings for an Orange County-based company in over three years, second ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA approves 1st rapid-acting insulin

Related topics